Sichuan Huiyu Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Sichuan Huiyu Pharmaceutical's earnings have been declining at an average annual rate of -20.2%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 20.9% per year. Sichuan Huiyu Pharmaceutical's return on equity is 3.7%, and it has net margins of 15.2%.
Key information
-20.2%
Earnings growth rate
-41.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -20.9% |
| Return on equity | 3.7% |
| Net Margin | 15.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Sichuan Huiyu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 932 | 142 | -2 | -19 |
| 31 Dec 23 | 927 | 134 | 0 | 0 |
| 30 Sep 23 | 932 | 103 | 487 | 351 |
| 31 Mar 23 | 1,265 | 168 | 688 | 372 |
| 31 Dec 22 | 1,493 | 249 | 812 | 356 |
| 30 Sep 22 | 1,652 | 294 | 902 | 341 |
| 30 Jun 22 | 1,772 | 358 | 981 | 309 |
| 31 Mar 22 | 1,863 | 430 | 1,020 | 272 |
| 31 Dec 21 | 1,824 | 446 | 972 | 248 |
| 30 Sep 21 | 1,781 | 478 | 1,096 | 213 |
| 30 Jun 21 | 1,664 | 439 | 1,199 | 199 |
| 31 Mar 21 | 1,537 | 405 | 834 | 119 |
| 31 Dec 20 | 1,364 | 343 | 771 | 89 |
| 31 Dec 19 | 707 | 177 | 390 | 56 |
| 31 Dec 18 | 54 | -22 | 57 | 39 |
Quality Earnings: 688553 has high quality earnings.
Growing Profit Margin: 688553's current net profit margins (15.2%) are higher than last year (13.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688553's earnings have declined by 20.2% per year over the past 5 years.
Accelerating Growth: 688553's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688553 had negative earnings growth (-15.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.1%).
Return on Equity
High ROE: 688553's Return on Equity (3.7%) is considered low.